Histamine H3-receptor activation inhibits dopamine synthesis in rat striatum

NeuroReport

Volumn 11, Issue 1, 2000, Pages 163-166

  Molina Hernández, Anayansi ^a   Nuñez, Alejandro ^a   Arias Montaño, José Antonio ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Dopamine; H3 receptor; Histamine; L DOPA; Striatum; Tyrosine hydroxylase

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; CALCIUM; DOPA; DOPAMINE; HISTAMINE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; NICKEL; OXIDOPAMINE; THIOPERAMIDE; TRITIUM; ADRENERGIC RECEPTOR BLOCKING AGENT; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA METHYLHISTAMINE; ALPHA-METHYLHISTAMINE; HISTAMINE AGONIST; HISTAMINE DERIVATIVE; POTASSIUM; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; CORPUS STRIATUM; DEPOLARIZATION; DOPAMINE METABOLISM; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; SYNAPTIC MEMBRANE; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; IN VITRO STUDY; METABOLISM; NEOSTRIATUM; PHYSIOLOGY; RADIOASSAY; SYNAPTOSOME; WISTAR RAT;

ANIMALS; DIHYDROXYPHENYLALANINE; DOPAMINE; HISTAMINE AGONISTS; MALE; METHYLHISTAMINES; NEOSTRIATUM; NEUROTRANSMITTER AGENTS; OXIDOPAMINE; POTASSIUM; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, HISTAMINE H3; SUBSTANTIA NIGRA; SYMPATHOLYTICS; SYNAPTOSOMES; TYROSINE 3-MONOOXYGENASE;

EID: 0034676870     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200001170-00032     Document Type: Article

References (27)

1. Schwartz JC, Arrang JM, Garbarg M et al. Physiol Rev 71, 1-50 (1991).
2. Wada H, Inagaki N, Yamatodani A and Watanabe T. Trends Neurosci 14, 415-418 (1991).
3. Hill SJ, Ganellin CR, Timmerman H et al. Pharmacol Rev 49, 253-278 (1997).
4. Arrang JM, Garbarg M, Lancelot J-C et al. Nature 327, 117-123 (1987).
5. Cumming P, Shaw C and Vincent SR. Synapse 8, 144-151 (1991).
6. Ligneau X, Garbarg M, Vizuete ML et al. J Pharmacol Exp Ther 271, 452-459 (1994).
7. Pollard H, Moreau J, Arrang JM et al. Neuroscience 52, 169-189 (1993).
8. Ryu JH, Yanai K, Iwata R et al. Neuroreport 5, 621-624 (1994).
9. Schlicker E, Fink K, Detzner M et al. J Neurol Transm 93, 1-10 (1993).
10. Arias-Montaño JA, Martínez-Fong D and Aceves J. Neuropharmacology 30, 1047-1051 (1991).
11. Arias-Montaño JA, Martínez-Fong D and Aceves J. Brain Res 569, 317-322 (1992).
12. Gray EG and Whittaker VP. J Anat 96, 79-84 (1962).
13. Lowry DH, Rosenbrough NJ, Farr AL et al. J Biol Chem 193, 265-275 (1951).
14. Hetey L, Kudrin VS, Shemanow AY et al. Eur J Pharmacol 11 3, 1-10 (1985).
15. García M, Florán B, Arias-Montaño JA et al. Neuroscience 80, 241-249 (1997).
16. Grefen CR and Wilson CJ. The basal ganglia. In: Björklund A, Hökfelt T, Swanson L, eds. Integrated Systems of the CNS, Part III (Handbook of Chemical Neuroanatomy, Vol 12). Amsterdam: Elsevier, 1996: 369-466.
17. Ryu JH, Yanai K, Xiao-Lan et al. Br J Pharmacol 118, 585-592 (1996).
18. Kaufman S. Adv Enzymol Relat Areas Mol Biol 70, 103-200 (1995).
19. El Mestikawy S, Glowinski J and Hamon M. Nature 302, 830-832 (1983).
20. Knorr AM, Wolf ME and Roth RH. Biochem Pharmacol 35, 1929-1932 (1986).
21. Chowdhury M and Fillenz M. J Neurochem 50, 624-629 (1990).
22. Leurs R, Smit MJ and Timmerman H. Pharmacol Ther 66, 413-463 (1995).
23. Endou M, Poli F and Levi R. J Pharmacol Exp Ther 269, 221-229 (1994).
24. Lovenberg TW, Roland BL, Wilson SJ et al. Mol Pharmacol 55, 1101-1107 (1999).
25. Alexander GE and Crutcher MD. Trends Neurosci 13, 266-271 (1990).
26. Chevalier G and Deniau JM. Trends Neurosci 13, 277-280 (1990).
27. Onodera K, Yamatodani A, Watanabe T et al. Prog Neurobiol 42, 685-702 (1994).